Radiology Partners petitions FDA for greater clarity around imaging AI regulations - Radiology Business

Radiology Partners, one of the largest radiology groups in the United States, has submitted a petition to the U.S. Food and Drug Administration (FDA) requesting clearer regulatory guidelines for artificial intelligence tools used in medical imaging. The petition highlights the growing complexity of AI applications in radiology and the need for standardized rules to ensure patient safety, compliance, and innovation.

The company argues that current regulations are fragmented and lack specificity, creating uncertainty for developers and healthcare providers. Without clear frameworks, the adoption of AI in radiology could be slowed, despite its potential to improve diagnostic accuracy and efficiency. Radiology Partners emphasizes that well-defined regulations would help balance innovation with patient protection.

The petition comes at a time when AI is increasingly integrated into radiology workflows, from detecting abnormalities in X-rays to assisting in MRI and CT scan interpretations. The lack of clarity has led to inconsistent compliance practices across the industry, prompting calls for a more structured approach from regulators.